EMA Recommends Granting a Marketing Authorisation for Poherdy By Ogkologos - April 10, 2026 157 0 Facebook Twitter Google+ Pinterest WhatsApp It is a biosimilar of pertuzumab which was authorised in the EU in 2013 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR NICE doesn’t recommend ibrutinib drug for those with Waldenstrom’s macroglobulinaemia May 23, 2022 New chemotherapy-free treatment for bowel cancer made available in Scotland September 14, 2021 Woman Has Unnecessary Double Mastectomy and Narrowly Avoids Hysterectomy After Bad... March 27, 2019 How to Strengthen Your Immune System: Part 1 September 17, 2020 Load more HOT NEWS Sacituzumab Govitecan Does Not Demonstrate a Statistically Significant OS Improvement in... Combination of Temozolomide and Capecitabine Associated with Improved PFS Compared to... ESMO Asia Congress 2023, 1-3 December 2023, Singapore Can Artificial Intelligence Help See Cancer in New, and Better, Ways?
